Systemic Mastocytosis - Pipeline Review, H2 2016

Published: Nov, 2016 | Pages: 106 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Systemic Mastocytosis - Pipeline Review, H2 2016, provides an overview of the Systemic Mastocytosis (Gastrointestinal) pipeline landscape.

Systemic mastocytosis is a disorder where mast cells are abnormally increased in multiple organs including the bone marrow. Symptoms include shortness of breath, low blood pressure, hives and swelling, itching, diarrhea, headache, flushing and musculoskeletal pain. Treatment includes antihistamines and more aggressive forms of Systemic mastocytosis require interferon or chemotherapeutic agents.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Systemic Mastocytosis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Systemic Mastocytosis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Systemic Mastocytosis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Systemic Mastocytosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I and Preclinical stages are 2, 4, 3 and 1 respectively.Systemic Mastocytosis.

Systemic Mastocytosis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Systemic Mastocytosis (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Systemic Mastocytosis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Systemic Mastocytosis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Systemic Mastocytosis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Systemic Mastocytosis (Gastrointestinal)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Systemic Mastocytosis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Systemic Mastocytosis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5

Introduction 6
Global Markets Direct Report Coverage 6
Systemic Mastocytosis Overview 7
Therapeutics Development 8
Pipeline Products for Systemic Mastocytosis - Overview 8
Systemic Mastocytosis - Therapeutics under Development by Companies 9
Systemic Mastocytosis - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Systemic Mastocytosis - Products under Development by Companies 13
Systemic Mastocytosis - Companies Involved in Therapeutics Development 14
AB Science SA 14
AbbVie Inc 15
Allakos Inc. 16
Arog Pharmaceuticals, Inc. 17
Blueprint Medicines Corporation 18
Bristol-Myers Squibb Company 19
Deciphera Pharmaceuticals, LLC 20
Novartis AG 21
Patara Pharma Inc 22
Stemline Therapeutics, Inc. 23
Systemic Mastocytosis - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
AK-002 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
BLU-285 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
crenolanib besylate - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
cromolyn sodium - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
dasatinib - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
DCC-2618 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
ibrutinib - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
masitinib - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
midostaurin - Drug Profile 84
Product Description 84
Mechanism Of Action 84
R&D Progress 84
SL-401 - Drug Profile 86
Product Description 86
Mechanism Of Action 86
R&D Progress 86
Systemic Mastocytosis - Discontinued Products 92
Systemic Mastocytosis - Product Development Milestones 93
Featured News & Press Releases 93
Nov 03, 2016: Blueprint Medicines to Present Preliminary Data from Ongoing Phase 1 Clinical Trial for BLU-285 in Advanced Systemic Mastocytosis at 2016 ASH Annual Meeting 93
Oct 31, 2016: Deciphera Pharmaceuticals to Present Clinical Data on DCC-2618 at 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 93
Oct 28, 2016: Blueprint Medicines to Present Preclinical Data and Provide Enrollment Updates for Phase 1 Clinical Trial for BLU-285 in Advanced Systemic Mastocytosis at ECNM Annual Meeting 2016 94
Sep 15, 2016: Allakos Begins Clinical Trials of AK002 in Patients with Systemic Mastocytosis 95
Jun 29, 2016: Novartis PKC412 (midostaurin) pivotal data published in NEJM show 60% response rate in advanced systemic mastocytosis (SM) 95
May 30, 2016: AB Science will Present Phase 3 Data in Severe Systemic Mastocytosis at the International 21St Congress of the European Hematology Association 95
May 02, 2016: AB Science has submitted to EMA the marketing authorization application for Masitinib in the Treatment of Severe Systemic Mastocytosis 97
Feb 01, 2016: AB Science announces that Rapporteurs appointed by the EMA have recommended to file a marketing authorization application for full approval for masitinib in severe systemic mastocytosis 97
Dec 07, 2015: AB Science announces results from Phase 3 randomized placebo-controlled trial of masitinib in adults with severe systemic mastocytosis unresponsive to optimal symptomatic treatment 100
Nov 30, 2015: AB Science Announces Positive Top-Line Results from Phase 3 Trial of Masitinib in Adults with Severe Systemic Mastocytosis 102
Sep 10, 2015: Blueprint Medicines Receives FDA Authorization to Advance Novel Drug Candidate into Clinical Trial for Systemic Mastocytosis 103
Dec 08, 2014: Blueprint Medicines Debuts Comprehensive Preclinical Data Set on First Selective Drug for Patients with Systemic Mastocytosis at 2014 American Society of Hematology Annual Meeting 104

Appendix 105
Methodology 105
Coverage 105
Secondary Research 105
Primary Research 105
Expert Panel Validation 105
Contact Us 105
Disclaimer 106

List of Tables

Number of Products under Development for Systemic Mastocytosis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 11
Comparative Analysis by Early Stage Development, H2 2016 12
Products under Development by Companies, H2 2016 13
Systemic Mastocytosis - Pipeline by AB Science SA, H2 2016 14
Systemic Mastocytosis - Pipeline by AbbVie Inc, H2 2016 15
Systemic Mastocytosis - Pipeline by Allakos Inc., H2 2016 16
Systemic Mastocytosis - Pipeline by Arog Pharmaceuticals, Inc., H2 2016 17
Systemic Mastocytosis - Pipeline by Blueprint Medicines Corporation, H2 2016 18
Systemic Mastocytosis - Pipeline by Bristol-Myers Squibb Company, H2 2016 19
Systemic Mastocytosis - Pipeline by Deciphera Pharmaceuticals, LLC, H2 2016 20
Systemic Mastocytosis - Pipeline by Novartis AG, H2 2016 21
Systemic Mastocytosis - Pipeline by Patara Pharma Inc, H2 2016 22
Systemic Mastocytosis - Pipeline by Stemline Therapeutics, Inc., H2 2016 23
Assessment by Monotherapy Products, H2 2016 24
Number of Products by Stage and Target, H2 2016 26
Number of Products by Stage and Mechanism of Action, H2 2016 28
Number of Products by Stage and Route of Administration, H2 2016 30
Number of Products by Stage and Molecule Type, H2 2016 32
Systemic Mastocytosis - Discontinued Products, H2 2016 92